Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Revenue data on record, last reported at $49.9 million in Q4 2025.

  • For Q4 2025, Revenue fell 11.83% year-over-year to $49.9 million; the TTM value through Dec 2025 reached $185.7 million, down 28.34%, while the annual FY2025 figure was $185.7 million, 28.34% down from the prior year.
  • Revenue reached $49.9 million in Q4 2025 per MRVI's latest filing, up from $41.6 million in the prior quarter.
  • Across five years, Revenue topped out at $244.3 million in Q1 2022 and bottomed at $41.6 million in Q3 2025.
  • Average Revenue over 5 years is $120.8 million, with a median of $71.8 million recorded in 2023.
  • Peak YoY movement for Revenue: surged 364.29% in 2021, then crashed 71.61% in 2023.
  • A 5-year view of Revenue shows it stood at $228.4 million in 2021, then decreased by 10.39% to $204.7 million in 2022, then crashed by 63.78% to $74.1 million in 2023, then decreased by 23.72% to $56.6 million in 2024, then dropped by 11.83% to $49.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $49.9 million in Q4 2025, $41.6 million in Q3 2025, and $47.4 million in Q2 2025.